{"_canonicalization":{"envelope_id":"axm_ + sha256(envelope minus {signature, axiom_id, anchors})","envelope_signature":"ed25519(envelope minus {signature, axiom_id})","json":"sort_keys=True, separators=(',',':'), ensure_ascii=False, allow_nan=False, utf-8","leaf_hash":"sha256(0x00 || canonical_json(envelope_full))","seal_signature":"ed25519(seal minus {signature, sig_algorithm})"},"axiom_id":"axm_6fe49fb275f54c652fcfc992e3b866670199655c1eb0e6051dcab38b77b8e026","bitcoin_anchor":{"bitcoin_attestations":[],"calendar_attestations":[],"ots_url":"","stamped_at":"","status":"pending_next_stamp"},"envelope":{"anchors":[{"chain":"crovia.axiom_graph","height":0,"merkle_proof":"spider_vendor_press_v1","root_at_anchor":"spider_vendor_press_v1"}],"axiom_id":"axm_6fe49fb275f54c652fcfc992e3b866670199655c1eb0e6051dcab38b77b8e026","axiom_type":"AX.OBS","body":{"axiom_subtype":"news.vendor_press.v1","category":"news","fingerprint":"2b0ff8f137d204233ac1a0ca25a70695a6751b7ad3e940bf6b279e635b5662a3","published":"Fri, 15 May 2026 00:00:00 -0400","receipt_hash":"2b0ff8f137d204233ac1a0ca25a70695a6751b7ad3e940bf6b279e635b5662a3","schema":"spider.news.vendor_press.v1","spider":"vendor_press","spider_record":{"axiom_subtype":"news.vendor_press.v1","category":"news","decision_hint":"POSITIVE","envelope_target":"AX.OBS","fingerprint":"2b0ff8f137d204233ac1a0ca25a70695a6751b7ad3e940bf6b279e635b5662a3","observed_at":"2026-05-15T04:43:17.611638Z","parent_run_hash":"5c64f85625fabd323e9c4a1cf068c012fb88a248deda9a9ac702fb2f9799f2e5","published":"Fri, 15 May 2026 00:00:00 -0400","runtime_version":"0.1.0","schema":"spider.news.vendor_press.v1","source_status":200,"source_url":"https://export.arxiv.org/rss/cs.AI","spider":"vendor_press","summary_excerpt":"arXiv:2605.14991v1 Announce Type: cross \nAbstract: Ovarian cancer is the most lethal gynecologic malignancy: around 60% of patients are diagnosed at an advanced stage, with an associated 5-year survival rate of about 30%. Early identification of non-responders to neoadjuvant chemotherapy remains a key unmet need, as it could prevent ineffective therapy and avoid delays in optimal surgical management. This work proposes a non-invasive deep learning framework to predict neoadjuvant chemotherapy response from pre-treatment contrast-enhanced CT by leveraging automatically derived 3D lesion masks. The approach encodes axial slices with a partially fine-tuned pretrained image encoder and aggregates slice-level representations into a volumetric embedding through an attention-based module. Training combines classification loss with supervised contrastive regularization and hard-negative mining to improve separation between ambiguous responders and non-responders. The method was developed on a ","title":"Predicting Response to Neoadjuvant Chemotherapy in Ovarian Cancer from CT Baseline Using Multi-Loss Deep Learning","url":"https://arxiv.org/abs/2605.14991","vendor":"arxiv_cs_ai"},"summary":"arXiv:2605.14991v1 Announce Type: cross \nAbstract: Ovarian cancer is the most lethal gynecologic malignancy: around 60% of patients are diagnosed at an advanced stage, with an associated 5-year survival rate of about 30%. Early identification of non-responders to neoadjuvant chemotherapy remains a key unmet need, as it could prevent ineffective therapy and avoid delays in optimal surgical management. This work proposes a non-invasive deep learning framework to predict neoadjuvant chemotherapy response from pre-treatment contrast-enhanced CT by leveraging automatically derived 3D lesion masks. The approach encodes axial slices with a partially fine-tuned pretrained image encoder and aggregates slice-level representations into a volumetric embedding through an attention-based module. Training combines classification loss with supervised contrastive regularization and hard-negative mining to improve separation between ambiguous responders and non-responders. The method was developed on a ","title":"Predicting Response to Neoadjuvant Chemotherapy in Ovarian Cancer from CT Baseline Using Multi-Loss Deep Learning","vendor":"arxiv_cs_ai"},"confidence":{"method":"deterministic"},"decision":"POSITIVE","issued_at":"2026-05-15T04:43:17Z","notes":"Spider vendor_press (news) news.vendor_press.v1","object":{"captured_by":"crovia.spider.vendor_press","primary_source_url":"https://arxiv.org/abs/2605.14991"},"predecessors":[],"schema":"crovia.axiom.v1","signature":"ed25519:03975e372b3a42e6e51e22b56f6ee63ec9c55a188ad7e6f413333c1873f3cd73f0fac6191f7a76f1be9e9726903246eca64b8996bf0a066aedda2106d5c0540b","signer":"crovia.substrate","subject":{"observed_at":"2026-05-15T04:43:17Z","source_collector":"spider:vendor_press","target_id":"https://arxiv.org/abs/2605.14991"},"tsa":{"authority":"crovia.substrate.bootstrap","rfc3161_token":"{\"kind\":\"crovia.bootstrap.tsa\",\"source_jsonl\":\"/opt/crovia/spider/data/news/vendor_press_v1.jsonl\",\"source_seal_merkle_root\":\"spider_vendor_press_v1\",\"upgrade_path\":\"Sessione H \\u2014 OpenTimestamps weekly anchor\"}"},"zk_mode":"clear","zk_proof":null},"ledger":{"leaf_hash":"5fa320e8788a7e9ed035081ad682a8b4b898d6f2ebe2e2659b14a744cbc2fef6","leaf_index":134650,"ledger_path":"/opt/crovia/substrate/axiom_ledger.jsonl"},"merkle_proof":{"hash_alg":"sha256","leaf_prefix":"0x00","node_prefix":"0x01","odd_leaf_rule":"duplicate_last","path":[{"sibling":"5815543d3cf5f3ff30ab94690ccde6f369567ff68c707f1c1f7b3dc1047e9576","side":"right"},{"sibling":"1ed3d26cd0a8b4d106e0a1cad9d575b36a0822942a6659caa68de84ee1ee67a5","side":"left"},{"sibling":"2c690cefd76169d8524588d2825f3e2d9de47142edc9f396b9905a014cff78c8","side":"right"},{"sibling":"a8e97968fcdc7d0ceda119a5a0a1eb9c9a12e0898651c0d5a3339c64a1817c8a","side":"left"},{"sibling":"1891d8d4400aa8e78756821136250c8966757bc95d1db730521fdcdffe155ee8","side":"left"},{"sibling":"d8a5a20d2c9f87798d5d5a7ddb6384d4d9c06d4b4e588b536b63981364617af9","side":"left"},{"sibling":"46f96cb7883dcb2712dad253af0583c5b367609f9717fd33426973df576e51f6","side":"left"},{"sibling":"cbbed0225164fe227925f0fc2929e9ecbc520f5a86b19035c412206d51935e10","side":"left"},{"sibling":"4711a7f4329f1874c3aa1ae93c336e1d4fa402bdd4b3d766c2a95304ea226882","side":"left"},{"sibling":"8ce2a4687a8ceb409df2e1cb10e44a610b21dc294e518a8550b6d1122335ca2b","side":"right"},{"sibling":"36672459e5ed50c64ee1842b69cb6d2eb682c2a04844555be8d124257571994a","side":"left"},{"sibling":"727783827652adfa99c455bd80a01bfb33836228e51068b4f654ef3da468ca69","side":"left"},{"sibling":"623194cd30880ed223e306737fdb111aa0d781751bfc47553c404a6af6aad2c4","side":"right"},{"sibling":"fc8f53ed42756907fb79ee19a4ed09f72c560e5302b3d98198b96bf1da635a4a","side":"right"},{"sibling":"d6607539da7ba39ec68be2d12f27ed6768766c745e3120fd915f88c5e288e07c","side":"right"},{"sibling":"b63408a424d27cd6a75e0fb155e69a58a328f41e9cb9dba1eddef9a5289cc7fd","side":"right"},{"sibling":"356fb36a4e188f03d7a05c54cd8789bdd40eda454b9bc9560f667acc08e6c4e0","side":"right"},{"sibling":"d841ad93efda0869e5eb97678f348f03f5caab4353e05ff4bf18f47fb945b822","side":"left"}]},"schema":"crovia.axiom_proof.v1","seal":{"first_collector_run_id":"","first_receipt_hash":"","jsonl_path":"/opt/crovia/substrate/axiom_ledger.jsonl","key_id":"430895f101d38164","last_collector_run_id":"","last_receipt_hash":"","leaf_count":134886,"merkle_root":"c6c7ae28c065bced89e7f844216b073f1a7cc4b378db0d41a98bcd21b28066db","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","run_id":"hourly_json_retrofit_20260515T053701Z","schema":"crovia.seal.v1","seal_family_version":"crovia-seal-family/1","seal_kind":"substrate_batch","sealed_at":"2026-05-15T05:37:26Z","sig_algorithm":"ed25519","signature":"5a3978c26017daf4104adbb3e1c3099c5750157acbfc7242ece1815dc6740fe08a690291ce0afe42011e20cc565b5ebe64ec016bf658b5bab563a63337985c05","signer_version":"1.1.0"},"trust_root":{"key_id":"430895f101d38164","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","signature_algorithm":"ed25519","url":"/registry/canon/TRUST_ROOT.md"},"verifier":{"spec":"/registry/canon/AXIOM_RECEIPT_v1.md","url":"/v/axm_6fe49fb275f54c652fcfc992e3b866670199655c1eb0e6051dcab38b77b8e026"}}